CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 23, 2020
Result type: Reports
Project Number: PC0222-000
Product Line: Reimbursement Review

Generic Name: dinutuximab

Brand Name: Unituxin

Manufacturer: United Therapeutics Corp.

Therapeutic Area: Neuroblastoma (pediatric)

Indications: For the treatment of pediatric patients with relapsed/refractory high-risk neuroblastoma in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor.

Manufacturer Requested Reimbursement Criteria1: To be used in combination with granulocyte macrophage colony-stimulating factor, irinotecan and temozolomide for the treatment of pediatric patients with high-risk neuroblastoma who have relapsed following consolidation treatment, or who did not achieve a durable remission following consolidation treatment.

Submission Type: Initial

Tumour Type: Neurological

Project Status: Received

Companion Diagnostics: No

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 22, 2020
Call for patient/clinician input closedDecember 10, 2020
Submission receivedNovember 23, 2020
Submission accepted-
Submit Feedback